Epilepsy comprises a set of neurologic and systemic disorders characterized by recurrent spontaneous seizures, and is the most frequent chronic neurologic disorder. In patients with medically refractory epilepsy, therapeutic options are limited to ablative brain surgery, trials of experimental antiepileptic drugs, or palliative surgery. Vagal nerve stimulation is an available palliative procedure of which the mechanism of action is not understood, but with established efficacy for medically refractory epilepsy and low incidence of side-effects. In this paper we discuss the recommendations for VNS use as suggested by the Brazilian League of Epilepsy and the Scientific Department of Epilepsy of the Brazilian Academy of Neurology Committee of Neuromodulation.
Epilepsy comprises a set of neurologic and systemic di sorders characterized by recurrent spontaneous seizures, and is the most frequent chronic neurologic disorder, with an estimated frequency of 4-10 in 1000 individuals per year 1 . In many cases, patients with epilepsy can maintain a normal and unrestricted life because antiepileptic drugs (AEDs) -the mainstay for epilepsy treatment -can provide satisfactory control or total relief of seizures. Nevertheless, despite considerable progress in drug and epilepsy research and carefully optimized AED treatment, approximately 35% of all epilepsy patients experience recurrent non-provoked spontaneous seizures 2 .
Patients with epilepsy may have severe impairment due to repetitive or prolonged seizures, with progressively impaired cognitive function, brain damage, and other neuropsychiatric deficits commonly occurring in pharmacoresistant or untreated patients 1 . In patients with medically refractory epilepsy, therapeutic options are limited to ablative brain surgery, trials of experimental AEDs, or palliative surgery 3 . All patients with failure in treatment with two or more appropriated AEDs, given in adequate dosage, may be conside red in this group 4 . In such cases, patients should be referred to centers specializing in epilepsy treatment, investigation and surgery. Brain resective surgery, when possible, usually gives the best chance for patients to be seizure free, but curative epilepsy surgery can only be performed in a subgroup of medically refractory patients in whom the epileptogenic focus can be localized and does not overlap with eloquent brain areas. In the other patients (with bilateral or multiple epileptogenic foci, with epilepsy onset in eloquent areas, or with no identifiable epileptogenic focus), palliative treatments such as a ketogenic diet, corpus callosotomy and vagal nerve stimulation can be offered if they suffer from disa bling seizures 5 . Even when these palliative treatments do not lead to complete control of seizures, a significant reduction of number and severity of seizures may be helpful for both patients and parents, reducing the risk of sudden unexpected death in epile psy (SUDEP), status epilepticus, severe traumas, hospitalization and emergency department visits, reducing total healthcare costs and increasing the independence and quality of life 6 . Corpus callosotomy dates from 1940 and its application and effectiveness in drop attacks and secondarily generalized tonic-clonic seizures has general acceptance for patients with intractable, non-resectable refractory epilepsy 7 . However, con troversy continues over the extent of corpus callosum resection, the risk of complication and patient selection. In large series, callosotomy was reported to render seizure-free outcome in 7.6% of patients, most of whom presented with drop-attack seizures 7 . Operative complications reported in earlier studies, such as hemiparesis, mesial hemispheric infarcts and hemispheric edema, were less frequent in recent series and most adverse events related to corpus callosotomy are transient and include neurologic deficits, mutism, apra xia, hemorrhage and postoperative infection 8 . Permanent focal neurologic deficits are rare.
Another available palliative procedure is neuromodulation. Neuromodulation strategies have been proposed to treat a variety of neurologic disorders, including medication-resistant epilepsy. Electrical stimulation of both central and peripheral nervous systems has emerged as a possible alternative for patients who are not deemed to be good candidates for resective procedures 9, 10 . The only neuromodulation procedure for treatment of epilepsy approved in Brazil is vagus nerve stimulation (VNS). Other forms of neuromodulation, such as facial or trigeminal nerve stimulation and deep brain stimulation, can only be used at an experimental level.
VAGus neRVe sTiMulATiOn
The vagus nerve is the largest cranial nerve and comprises large myelinated A fibers, small myelinated B fibers, and unmyelinated C fibers. About 80-90% of its fibers are afferent, encoding predominantly visceral sensory non-pain information, and emerge from, or converge to, four nuclei: the dorsal nucleus of the vagus nerve, the nucleus ambiguus, the solitary tract nucleus and the spinal trigeminal nucleus 11 . Assymetric heart innervations play an important role: the right vagus nerve is intimately associated with atriums and the left nerve with ventricles, and owing to the fact that the vagus innervation of the ventricles is less dense than that of the atriums, left VNS is less associated with arrhythmias 11 . Despite many studies, the exact mechanism by which VNS reduces seizure frequency is unknown, and many theories are have been proposed. It is believed that VNS may modulate electrical stimuli to the nucleus tractus solitarius and the brainstem reticular formation 12 . In this way, VNS may interrupt the synchronous electrical activity characteristic of seizures 13, 14 . Earlier research has attempted to characterize the mechanism of action of VNS by using EEGs, evoked potentials, cerebrospinal fluid (CSF) neurochemistry and functional imaging. CSF studies have shown a significant increase in gamma-aminobutyric acid (GABA) after 3-4 months of VNS treatment, but no significant decrease in glutamate, aspartate or 5-hydroxyindoleacetic acid (5-HIAA) levels after 3 to 9 months of VNS treatment. Non-responders had the greatest effect on neurotransmitter levels 15 . Long-term VNS had no effect on interictal EEG background or epileptiform activity, and no effect on visual or auditory evoked potentials. One report showed an increase in the N13-N20 interpeak interval with prolonged VNS 16 . Although the VNS mechanism of action is essentially unknown, a number of studies using functional imaging techniques, such as single-photon emission computed tomography (SPECT) and positron emission tomography (PET), have demonstrated widespread changes in blood flow and meta bolism in several cortical and subcortical regions during short-term VNS use 17 . These widespread changes in blood flow and metabolism in various cerebral structures have formed the foundation of hypotheses that attempt to explain the VNS effect 18 . Many pre-clinical studies have been performed on dogs, monkeys and rats to demonstrate that VNS was effective in the prevention, or reduction in the intensity and duration, of seizures [19] [20] [21] [22] [23] [24] . Following this research, five studies (E1E5) were performed in humans to evaluate the efficacy and safety of VNS for clinical use. The first studies (E1 and E2) were blind, 2year pilot studies of 14 patients with focal epilepsy. The third study (E3) was a randomized, double-blind and casecontrol study of 114 patients with focal epilepsy, followed for 2 years. The fourth study (E4) was a comparative use study in 124 patients with all type of seizures. The final study (E5) was a randomized, double blind, case-control study of 199 patients with focal epilepsy in 1995-1996. In all studies, 454 patients were given VNS implants, and 440 patients yielded assessable data. An approximate 50% seizure reduction post implantation occurred in 36.8% of patients at 1 year, in 43.2% at 2 years, and in 42.7% at 3 years. Median seizure reductions compared with baseline were 35% at 1 year, 44.3% at 2 years, and 44.1% at 3 years 25, 26 . As a consequence of these studies, prolonged, intermittent electrical stimulation of the left cervical portion of the vagus nerve was established as efficacious therapy of medically refractory epilepsy. Subsequent clinical investigations reported evidence of incremental seizure reductions over the Scientific Department of Epilepsy of the Brazilian Aca demy of Neurology (Brazilian Chapter of the World Fe deration of Neurology) suggest that VNS should be considered for patients with refractory epilepsy at any age in the following cases: 1. Patients who have failed to become seizure free fol lowing adequate trials (whether as monotherapies or in combination) of two tolerated and appropriately chosen and used firstgeneration AEDs (phenobarbital, phenytoin, carbamazepine, valproic acid) 4 plus another trial with at least one second-or third-generation AED (oxcarbazepine, lamotrigine, topiramate, vigabatrin, clobazam, levetiracetam); 2. Patients who have been previously evaluated at specialized secondary-or tertiary-level epilepsy centers with the aim of diagnosis confirmation and exclusion of epilepsy surgery as a treatment option (owing to unacceptable neurologic deficits, high surgery risk or refusal of the patient to undergo epilepsy surgery); 3. Patients with indication for invasive evaluation (i.e. intracranial electrodes should first be inserted and, if epilepsy surgery is not recommended, they should then be considered for VNS implantation); 4. Patients with ultra-refractory status epilepticus; 5. Patients with idiopathic generalized epilepsy or progressive epilepsy who meet the abovementioned requirements should receive an in-depth consultation, and should only be considered for implantation with the agreement of at least two secondary-or tertiary-level epilepsy center teams.
ReCOMMendATiOns FOR Vns MAnAGeMenT
VNS stimulation parameters should be adjusted individually for each patient. However, the treatment of certain variables remains the same for all patients. The VNS generator is usually turned on 1-2 weeks after implantation, with a progressive increase in output current. A faster current increment may be attempted if the patient tolerates therapeutic levels in a single visit 41 . Typical values for a satisfactory response should be 1-2 milliamps, but values between 0.25 and 3.5 milliamps are possible. Other values that may be adjusted at follow up are signal frequency, pulse width, signal ontime and signal offtime. If seizure frequency reduction is not satisfactory at 1.5 milliamps, signal on-time may be increased or signal offtime decreased. In cases of intolerable or permanent sideeffects, pulse width and current output may be temporarily reduced. Adjustments should be made at an interval of at least one week until stimulation reaches 0.75 or 1 milliamp, and then at intervals of 1 month for the first six months, followed by 3-month intervals.
Special care should be given to patients requiring longterm follow-up because the generator's battery usually needs months of ongoing vagus nerve stimulation and VNS efficacy in generalized epilepsy 27 . In addition to decreasing seizure frequency, an improvement in mood was witnessed in patients who had received VNS, even in those with little or no change in seizure frequency 28 . Clinical studies showed a 31% response after 3 months of VNS therapy, with further improvements at 6 and 12 months 29 . Most postimplantation adverse effects are relatively mi nor, and the most common effects at 1 year encompass hoarseness (28%) and paresthesia (12%), at 2 years hoarseness (19.8%) and headache (4.5%), and at 3 years shortness of breath (3.2%). These adverse events change over time, and have a tendency to diminish or disappear 30 . VNS therapy is considered a palliative treatment in patients with confirmed drugresistant epilepsy, without indication of resective brain epilepsy surgery, for all types of seizures in adults and children [31] [32] [33] [34] and has been used to treat pharmacoresistant epilepsy in Europe since 1994. In USA, the Food and Drug Administration (FDA) approved VNS in July 1997 for use as an adjunctive therapy for adults or adolescents older than 12 years with medically refractory partial onset seizures 35 . A Brazilian study evaluating 36 patients demonstrated at least 50% seizure reduction in 61.3% of implanted patients, concluding that VNS should be conside red as a treatment option even in countries with limited resources 36 . There is insufficient confirmation about the efficacy and safety of VNS implantation in patients with idiopathic generalized epilepsy (IGE) or progressive epilepsy. Some authors have suggested that at least some patients with IGE 37, 38 or progressive forms of epilepsy 39 can benefit from this procedure. In Brazil, VNS is approved by ANVISA (' Agência Nacional de Vigilância Sanitária', or National Health Surveillance Agency) for use in patients who have been diagnosed with refractory, focal or generalized epilepsy for 2 or more years. However, patients' suitability for VNS implantation needs further discussion. In a recent meta-analysis 40 , VNS was considered effective and relatively safe as adjunctive therapy in patients with medically refractory epilepsy not suited to brain resective surgery or in patients who failed to become seizure free after epilepsy surgery. In this study, the authors found that children experienced a slightly better outcome than adults. Also, patients with generalized epilepsy benefi ted more than those with partial seizures. In terms of epilepsy etiology, the best outcomes were observed in patients with post-traumatic epilepsy and with tuberous sclerosis 40 .
ReCOMMendATiOns FOR Vns use
Considering all these published data, the Brazilian League of Epilepsy Committee of Neuromodulation (Bra zilian Chapter of the International League Against Epilepsy) and to be replaced after 5-10 years, depending on the intensity of the stimulation used. In the new models it is possible, when testing the operation of the generator, to evaluate the battery level and thereby monitor patients more closely. If the gene rator battery runs out of charge, the device is switched off and the patient may experience an increase in seizure frequency, so it must be replaced as soon as possible.
In conclusion, the use of implanted devices has become an interesting and potentially useful tool in the therapeutic strategy for patients with epilepsy. VNS belongs to this category and, considering that it has already been approved for clinical use since years ago, one would expect that systematic and objective indication for implantation should be available. In practical terms, this is not the case. At first glance, VNS is a technology that represents an economic challenge for most healthcare systems. However, the investment could be justified in terms of the potential of VNS to reduce seizure frequency and, consequently, to improve efficiency and sa vings in medical resources, which would then become either unnecessary or reduced. Yet this only applies to those ca ses in which there is total or partial control of seizures and an eventual improvement overall. This outcome occurs in only a portion of implanted patients. Notwithstanding the current study, evidence suggests that, when compared with VNS implants, epilepsy surgeries have consistently shown better results in terms of seizure control. Thus, the costs and be ne fits should be carefully considered when this particular method is indicated.
The Brazilian League of Epilepsy, here represented by its Committee of Neuromodulation, as well as the Brazilian Academy of Neurology, here represented by its Scientific Department of Epilepsy, are medical societies responsible for monitoring epilepsy (including both training and medical/ general education and evaluating the potential diagnostic and therapeutic resources). They are in agreement that tertiary-level epilepsy centers should determine whether VNS is indicated and should perform the implants. This would seem to be a reasonable approach, considering that VNS implantation represents an adjuvant technology, with an indication in patients whose clinical resistance is clearly established and in patients who are not considered good candidates for epilepsy surgery for many different reasons. Our current understanding of this degree of reliability can be defined only by trained and professional staff with access to all forms of diagnostic tools and surgical treatment of epilepsy, ensuring that the patient has access to the best possible care. Only with such rigor, together with narrow indication, can the cost and benefit ratio of VNS be properly estimated.
